Merck KGaA (MKGAY) Receives $59.60 Consensus PT from Analysts
Shares of Merck KGaA (OTCMKTS:MKGAY) have earned an average rating of “Buy” from the twelve research firms that are currently covering the firm. Six research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $59.60.
Separately, Berenberg Bank lowered Merck KGaA from a “buy” rating to a “hold” rating in a report on Friday, August 12th.
Merck KGaA (OTCMKTS:MKGAY) opened at 34.69 on Tuesday. Merck KGaA has a 1-year low of $26.91 and a 1-year high of $37.16. The stock has a 50 day moving average of $0.00 and a 200 day moving average of $0.00.
Merck KGaA Company Profile
Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company diversifies its activities into four business divisions: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin.
Receive News & Stock Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related stocks with our FREE daily email newsletter.